The cause of myasthenia gravis is due to a problem with the body’s immune system. The patient’s immune system produces some autoantibodies that mistakenly attack the junction between nerves and muscles, affecting normal muscle function. The onset of myasthenia gravis can be seen at all ages, and the peak of the onset is around the age of 30 and 50. Epidemiological surveys show that the incidence rate of myasthenia gravis in China is 0.68/100,000 people. Among them, the 70-74 age group has the highest incidence rate. Given that their disease is underdiagnosed, the real number could be much higher, and there is no cure, with medications that can only alleviate symptoms.
The product CAN106 of Beihai Kangcheng, a leading global biopharmaceutical company focusing on the field of rare diseases in China, has been granted Orphan Drug Designation by the US Food and Drug Administration (FDA) for the treatment of myasthenia gravis. It is in the research and development stage, but for patients around the world, this is a drug worth looking forward to.
Beihai Kangcheng scientific research team
